Open the packet of SINGULAIR 4-mg oral granules.
- Do not open the packet until you are ready to give SINGULAIR 4-mg oral granules to the patient.
- Contents of 1 packet=1 dose.
Oral granules packet shown not actual size.
For more details on the timing of dosing, please read the Dosage and Administration section of the
Prescribing Information.
SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).
SELECTED SAFETY INFORMATION
- Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
- In clinical trials in patients with allergic rhinitis, adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
- SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.
Before prescribing SINGULAIR, please read the Prescribing Information.
20951837(3)-02/10-SNG
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PRIVACY POLICY